Quantum BioPharma Ltd. (NASDAQ: QNTM) was recently highlighted in a Men’s Fitness article by Lakshan Weeraratne that examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The coverage brings attention to early-stage data that could influence the growing market for alcohol recovery products, while also emphasizing the need for further rigorous research.
The company-sponsored, placebo-controlled study involved 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. These findings suggest potential benefits for certain alcohol recovery measures, which could be of interest to consumers and investors alike.
However, the Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. While the findings are promising, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive—an important distinction for public safety.
For Quantum BioPharma, the publicity comes as the company continues to build a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on developing its lead compound, Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. The company invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The Men’s Fitness feature underscores the broader interest in alcohol recovery solutions and the importance of transparency in clinical research. For readers and industry observers, the story serves as a reminder that early-stage results, while encouraging, must be interpreted with caution. The article’s balanced approach—highlighting both the potential benefits and the study’s shortcomings—provides a factual basis for evaluating Unbuzzd’s prospects.
Investors and stakeholders can find more information about Quantum BioPharma through the company’s newsroom at https://ibn.fm/QNTM. The news was disseminated via BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Full terms of use and disclaimers are available on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
